ARTICLES IN THREE SENTENCES
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells
This pre-clinical study evaluated a chimeric antigen receptor construct characterized by a novel anti-CD30 single-chain variable-fragment cassette, linked to CD3ζ by the signaling domains of CD28.4-1BB or CD28.OX40. The authors concluded that the CD28.OX40 co-stimulatory combination is a very promising therapeutic strategy for patients with CD30+ non-Hodgkin lymphoma or Hodgkin lymphoma.
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies
This clinical study retrospectively evaluated the effect of romiplostim in 173 patients with solid tumor, lymphoma or myeloma and chemotherapy-induced thrombocytopenia. Romiplostim was effective in patients with solid tumors: 79% avoided chemotherapy dose reductions/treatment delays, and 89% avoided platelet transfusions. The rate of response to romiplostim in patients with hematologic malignancies was 10%.
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
The authors of this study determined the combined activity of venetoclax and FLT3-ITD inhibition in preclinical models of FLT3-ITD+ acute myeloid leukemia. They observed that FLT3-ITD inhibition combined with venetoclax had impressive anti-tumor activity and suggest that results of this study provide a strong mechanistic rationale for clinical studies.
In this study the gene expression profiles of β-thalassemia intermedia and major were analyzed by RNA sequencing. This approach identified sex differences suggesting that males and females are differentially affected by β-thalassemia. This finding highlights the need for considering sex as an important variable of the disease which should be considered when developing differential diagnostic and therapeutic strategies.
TAKE ADVANTAGE FROM HAEMATOLOGICA